公开(公告)号：EP2097534A2

公开(公告)日：2009-09-09

申请号：EP07871698.2

申请日：2007-12-13

申请人： MEDAREX, INC.

发明人： COCCIA, Marco A. ,  TERRETT, Jonathon A. ,  KING, David John ,  PAN, Chin ,  CARDARELLI, Josephine ,  YAMANAKA, Mark ,  HENNING, Karla Ann

IPC分类号： C12P21/08

CPC分类号： C07K16/2875 ,  A61K47/65 ,  A61K47/6809 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure.